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Abstract
Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the bronchial and gastrointestinal tract and 
can produce hormones leading to distinct clinical syndromes. Systemic treatment of patients with unresectable NETs aims 
to control symptoms related to hormonal overproduction and tumor growth. In the last decades prognosis has improved as 
a result of increased detection of early stage disease and the introduction of somatostatin analogs (SSAs) as well as sev-
eral new therapeutic options. SSAs are the first-line medical treatment of NETs and can control hormonal production and 
tumor growth. The development of next-generation multireceptor targeted and radiolabelled somatostatin analogs, as well 
as target-directed therapies (as second-line treatment options) further improve progression-free survival in NET patients. 
To date, however, a significant prolongation of overall survival with systemic treatment in NET has not been convincingly 
demonstrated. Several new medical options and treatment combinations will become available in the upcoming years, and 
although preliminary results of preclinical and clinical trials are encouraging, large, preferrably randomized clinical studies 
are required to provide definitive evidence of their effect on survival and symptom control.
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Key Points 
Therapeutic options for symptom control in functioning 
neuroendocrine tumors (NETs) are still limited, espe-
cially in progressive disease
Novel targeted systemic treatment options have become 
available for NET patients in the last years, but their 
effect on overall survival is still controversial.
Randomized clinical trials that compare, combine, and 
sequence current and potential novel therapies are press-
ingly required.
1 Introduction
The endocrine system is composed of neuroendocrine cells 
dispersed throughout the entire body. These cells can be 
found in isolation or may form small aggregates [1]. Neu-
roendocrine tumors (NETs) originate from these cells [1, 2], 
and this heterogeneous group of neoplasms displays a wide 
range of biological behavior ranging from benign behavior 
with a life expectancy of decades to highly malignant clini-
cal behavior with a very limited life expectancy [3]. Tumor 
heterogeneity is also reflected in the categorization of these 
tumors, which includes primary tumor localization (e.g., 
lung, pancreas, stomach, small bowel, colon), tumor grade, 
functional activity, disease stage, and susceptibility to drug 
treatment [4, 5]. NETs are histologically graded into well 
differentiated (grade 1, 2, or 3 NETs) or poorly differenti-
ated (neuroendocrine carcinomas) tumors [5]. Locoregional 
or oligometastatic well-differentiated NETs are candidates 
for surgical resection with curative intent. However, a con-
siderable subset of patients presents with irresectable or 
metastasized disease and consequently requires palliative 
systemic treatment.
According to the last National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results (SEER) sta-
tistics, the incidence of NETs has increased substantially 
(1.09/100,000 persons in 1973 to 6.98/100,000 in 2012), 
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especially for lung, small intestinal, and rectum NETs. In 
this context, the rate of patients with localized disease at 
the time of diagnosis has increased in the last years, which 
allowed for improved surgical resection rates and progno-
sis. However, survival has also improved for patients with 
advanced stages of gastroenteropancreatic-(GEP-)NETs, 
which is partially explained by the introduction of somato-
statin analogs (SSAs) [6].
SSAs are the cornerstone of systemic treatment of well-
differentiated, locally advanced or metastatic NETs [7–9]. 
SSAs act through binding to G-protein-coupled somatostatin 
receptors (SSTRs), which are broadly expressed in NETs and 
can modulate hormone secretion and tumor cell prolifera-
tion [10–12]. Although SSAs can induce sustained disease 
stabilization, resistance to treatment frequently occurs after 
prolonged use, even when dose-intensification has been 
pursued. Various alternative approaches can be considered 
here, e.g., the use of radiolabeled SSAs [13], the application 
of specific inhibitors of various tumor-cell signal transduc-
tion pathways and/or angiogenesis [14, 15], and the use of 
chemotherapy [16]. Additionally, new therapeutic options 
for functioning NETs have been developed [17, 18], and 
several novel treatments are currently under study [19, 20]. 
Considering the more recent advances in systemic treatment 
in NETs, an overview of the currently available treatment 
options for advanced functional as well as non-functional 
NETs is presented, as well as an overview of novel therapeu-
tic options and clinical trials. We will not discuss systemic 
chemotherapy or neuroendocrine carcinomas.
2  Control of Hormonal Overproduction
NETs may cause specific clinical syndromes due to an 
overproduction of hormones and bioactive peptides. The 
incidence of functioning NETs ranges from 0.01–8.4 cases 
per 100,000 per year, depending on the secreted hormone. 
Carcinoid syndrome is the most frequent hormone-related 
syndrome within NETs (2–8.4 new cases/100,000/year) and 
is predominantly encountered in patients with metastasized 
midgut NETs [21, 22]. SSAs are considered to be the pre-
ferred first-line treatment option in functionally active NETs, 
including those associated with the carcinoid syndrome and 
functional pancreatic neuroendocrine tumors (PNETs) [11, 
23]. The mechanisms of action of current medical options 
for functioning NETs are depicted in Fig. 1.
2.1  Carcinoid Syndrome (CS)
Carcinoid syndrome (CS) is mediated by several hormones, 
especially serotonin, and comprises several symptoms 
including flushing (94%), diarrhea (78%), carcinoid heart 
disease (CHD) (53%), and abdominal pain (51%) [24]. The 
role of SSAs on this often highly symptomatic secretory 
diarrhea and flushes was initially described in 1978 [25–27]. 
Since then, short-acting octreotide has been considered as 
a treatment option for carcinoid syndrome. The efficacy of 
short- and long-acting octreotide is similar once steady-state 
circulating concentrations of octreotide are achieved [27, 
28]. Long-acting preparations of SSAs are widely used, 
probably due to their efficacy, but also to the comfortable 
administration every 28 days (in short-acting preparations, 
drug administration every 8 h may limit treatment compli-
ance). SSAs improve flushes and diarrhea in 53–75% and 
45–80% of cases, respectively [29, 30]. Long-acting octreo-
tide and lanreotide similarly reduce urinary 5-hydroxyin-
doleacetic acid (u5-HIAA) and improve quality of life in 
NET patients [29]. Both octreotide and lanreotide are gener-
ally well tolerated, and side effects include gastrointestinal 
discomfort, headache, hyperglycemia, and the formation of 
bile stones [29].
Despite the effectiveness of SSAs, loss of response can 
occur after prolonged use. Tachyphylaxis, downregulation 
of cell surface SSTRs, and development of antibodies to 
SSAs have been hypothesized to underlie treatment resist-
ance to SSAs [31–33]. In patients with refractory symptoms, 
intensified schedules consisting of either increased dose or 
increased frequency of administration have been found to 
control symptoms in about 40–81% of patients, without 
additional adverse events [34, 35]. Addition of short-act-
ing octreotide (ranging from 100 to 500 µg every 8 h) is an 
alternative approach in case of treatment-refractory disease 
[36, 37]. In addition, favorable clinical response on carci-
noid syndrome-related symptoms has also been reported in 
patients after treatment with peptide receptor radionuclide 
therapy (PRRT) [38, 39].
The use of serotonin-3-receptor antagonists (ondansetron) 
[40] and antidiarrheal drugs (loperamide) in combination 
with SSAs may improve episodes of diarrhea [41]. Pasire-
otide, a SSA with affinity to multiple SSTRs, has also been 
tested in patients with octreotide LAR-resistant tumors. 
Pasireotide showed efficacy in 33% of patients when admin-
istered at 150 µg twice daily, escalated to a maximum dose 
of 1200 µg per day [42]. However, a randomized phase III 
study of pasireotide LAR versus high-dose (40 mg) octreo-
tide LAR for symptom control in patients with advanced 
GEP-NETs, whose disease-related symptoms were uncon-
trolled by first-generation SSAs at maximum approved 
doses, failed to show superiority of pasireotide LAR [43]. 
α-Interferon in combination with octreotide has been sug-
gested as an effective treatment for symptom control, but 
unfortunately the use of this combination is limited due to 
the high rate of adverse effects attributed to α-interferon 
[44].
Recently, telotristate etiprate, a novel inhibitor of 
tryptophan hydroxylase, the rate-limiting enzyme in the 
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biosynthesis of serotonin, has been developed [45]. This 
drug is able to suppress serotonin production in patients 
with NETs, as indicated by a decrease in u5-HIAA, with a 
concomitant partial improvement of diarrhea [17, 18, 46]. 
An international, multicenter, randomized, double-blind, 
placebo-controlled phase III trial (TELESTAR) reported 
a reduction of approximately 40% of bowel movements 
per day using telotristat etiprate doses of 750–1500 mg 
[45]. Furthermore, reductions of ≥ 30% in u5-HIAA levels 
have been reported with this drug [18, 47]. In this sense, a 
higher decrease in u5-HIAA has been associated with bet-
ter improvement in bowel movements [18]. Recently, the 
phase III companion study TELECAST reported a statisti-
cally significant reduction in bowel movements in about 40% 
of patients, even in patients who were not on SSAs therapy. 
Unfortunately, the lack of patients in this last category (or 
that were assigned to the placebo group) limits conclusions 
in this respect [17]. Importantly, stool form improved in 20% 
and flushing in 27% of cases [18]. It seems therefore that 
a subset of patients with midgut NETs treated with SSAs 
may benefit from telotristat etiprate. Some adverse effects 
have been reported (including increase in transaminases and 
gastrointestinal symptoms, especially nausea) not result-
ing in treatment discontinuation [18, 45]. Some preclinical 
studies suggest that telotristat etiprate does not cross the 
blood-brain barrier ([Lexicon, unpublished observations in 
[18]). The TELESTAR study reported a higher incidence 
of depression-related events in patients receiving telotristat 
ethyl 500 mg three times per day, but not in those patients 
receiving 250 mg three times per day (similar incidence to 
placebo) [45]. This finding was not observed in the TEL-
ECAST study, however [17]. Finally, lowering circulating 
serotonin levels by telotristat etiprate may also be important 
to counteract the development of NET-associated cardiac 
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Fig. 1  Current medical treatment for symptoms control in neuroen-
docrine tumors. Short- and long-acting and radiolabeled somatosta-
tin analogs bind to G-protein linked receptors on the cell surface with 
variable affinity. Decreases in cAMP and intracellular calcium levels 
inhibit hormone release. Somatostatin influences hormone secretion 
and motility in the whole gastrointestinal tract. Serotonin production 
may also be decreased by telotristat, which inhibits the rate-limiting 
step in the serotonin secretion (the enzyme tryptophan hydroxylase). 
sstr somatostatin receptor, SSAs somatostatin analog, PRRT peptide 
receptor radionuclide therapy, cAMP cyclic adenosine monophos-
phate, VIP vasoactive intestinal peptide, PP pancreatic polypeptide, 
SST somatostatin
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and mesenterial fibrosis, in which serotonin is thought to 
play a major role [48, 49].
2.1.1  Carcinoid Heart Disease
Tumor-secreted vasoactive hormones may also produce the 
deposition of plaques on the endocardial surfaces of valve 
leaflets, the subvalvular area, and cardiac chambers, affect-
ing especially the right side of the heart, and resulting in 
carcinoid heart disease (CHD) [50]. CHD affects about 50% 
of patients with CS [51]. SSAs and/or tumor-debulking pro-
cedures may improve the hemodynamic impact of tumor 
vasoactive agents on CHD [28, 52, 53], but there is no con-
vincing evidence that these treatment options can stop the 
progression of CHD [54].
The initial treatment of decompensated CHD consists of 
loop diuretics, fluid and salt restriction, and compression 
stockings. However, in advanced stages these treatments 
may become ineffective [55]. In those cases, cardiac valve 
surgery or balloon valvuloplasty is recommended [50]. 
When surgery is required, continuous octreotide infusion 
(50–100 μg/h) should be administered 2 h before until 24 h 
after the surgical procedure in order to prevent carcinoid cri-
sis and its complications [56]. Antihistaminic drugs and cor-
ticosteroids may also be used before surgery [55], whereas 
the use of drugs (opioids, dopamine, adrenaline/epinephrine) 
that precipitate the release of vasoactive products should be 
avoided [56, 57]. In addition, the effect of telotristat etiprate 
in CHD should also be evaluated.
2.2  Insulinoma
Most insulinomas are small, benign tumors that can be sur-
gically cured. Unfortunately, the clinical management of 
patients with metastatic insulinomas may be difficult. Apart 
from oral or intravenous glucose administration, several 
medical options are available to treat hypoglycemia in the 
preoperative setting or in case of metastatic disease. Diazox-
ide is a well-known drug to treat hypoglycemia in patients 
with insulinomas. It is a benzothiadiazide derivative that 
inhibits insulin secretion via ATP-dependent potassium 
channels in pancreatic β-cells. It also increases hepatic glu-
cose production and inhibits tissue glucose uptake, improv-
ing hypoglycemia in 50–60% of cases [58–62]. It should 
be initiated in low doses (150–200 mg/day) administered 
two or three times daily until a maximum of 600–800 mg. 
If after 2–3 weeks of treatment any clinical improvement 
is observed, diazoxide may be stopped [63, 64]. Adverse 
effects are observed in about the half of patients and include 
water retention, hirsutism, weight gain, nausea, emesis, diar-
rhea, abdominal pain, headache, and rash [58, 59, 65].
SSAs (octreotide LAR and lanreotide autogel) are prefer-
ably used in malignant insulinomas, where the activation of 
SSTR (if expressed) decreases insulin release [66]. Unfor-
tunately if SSTR expression is low or absent, SSAs may 
paradoxically lower blood glucose levels by suppressing 
glucagon release [60]. Insulin secretion is also inhibited via 
the SSTR type 5 (SSTR5) [67]. Since the affinity of pasire-
otide for SSTR5 is 30- to 40-fold higher when compared 
with octreotide [68], pasireotide may be an alternative thera-
peutic option in malignant insulinomas. Some cases reports 
described an appropriate glucose control with pasireotide 
in insulinomas resistant to other treatment options includ-
ing octreotide LAR, everolimus, or chemotherapy [69, 70].
Blood glucose normalization in patients with malignant 
insulinomas has also been reported after treatment with 
everolimus when previous treatment options (octreotide 
LAR, chemotherapy, PRRT, or radiofrequency ablation) 
failed to achieve appropriate glucose control [65, 71, 72]. 
Clinical effect may be achieved after 2 weeks of treatment 
with 10 mg everolimus per day [63]. Everolimus can proba-
bly decrease insulin release through the AMP-activated pro-
tein kinase (AMPK)/c-Jun N-terminal kinase (JNK)/FoxO 
pathway, and it may also induce peripheral insulin resistance 
by downregulation of glucose transporter 1 (GLUT1) via 
reduced transcription and translation [71, 73–75].
PRRT can also be a successful therapeutic alternative 
in metastatic insulinomas with SSTR expression [76]. In 
a small patient series PRRT induced stable disease for 
18–50 months and no hypoglycemic episodes occurred 
during that period [76]. Clinical improvement despite the 
presence of the tumor suggested a sustained effect of PRRT 
on insulin secreting machinery [60].
2.3  Glucagonoma
This rare tumor originating from α-pancreatic cells may cause 
the glucagonoma syndrome, which is characterized by the 
presence of necrolytic migratory erythema (NME), diabe-
tes mellitus, and weight loss; other symptoms include ane-
mia, glossitis, steatorrhea, diarrhea, venous thrombosis, and 
neuropsychiatric disturbances [77]. If surgery is performed, 
resection of the tumor load of at least 70–90% is necessary 
for symptom control, which may be difficult in several cases. 
Clinical symptoms may improve with SSAs (octreotide and 
lanreotide) [77]. Specifically, the NME may improve despite 
the persistence of elevated serum glucagon levels [78]. Pasire-
otide has also been suggested as an appropriate therapeutic 
option in octreotide-resistant tumors [77, 79]. In addition, 
sunitinib and everolimus have been reported as successful 
treatment options in these functioning tumors and both have 
been associated with increased progression-free survival (PFS) 
when compared to placebo [80, 81]. PRRT with 90Yttrium-
DOTATOC or 177Lu-DOTATATE may induce disease stabi-
lization or regression with subsequent symptom control [82], 
but series focusing only on glucagonomas are still lacking.
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2.4  Gastrinoma
Gastrinomas are sporadic in 75% of cases. In these tumors, 
surgery is curative only in about 60% [83]. Surgical resec-
tion is also controversial in patients with multiple endocrine 
neoplasia syndrome type I due to a low probability of cure 
[84]. Consequently, medical treatment is necessary in a con-
siderable number of patients [85].
Gastric hypersecretion and related symptoms should be 
treated with high-dose  H+-K+-ATPase proton-pump inhibi-
tors (PPIs) [83]. Serum levels of vitamin B12 and iron 
should be monitored at least once a year [86, 87].
Since SSTRs are widely expressed in gastrinomas 
[88], SSAs (octreotide and lanreotide) effectively sup-
press gastrin secretion and decrease or normalize gas-
tric acid secretion in over half (50–100%) of gastrinoma 
patients [86, 89–91]. Their use has been associated with 
tumor stabilization in 47–75% of patients [91, 92], and 
SSAs may be combined with chemotherapy in metasta-
sized gastrinomas [93]. In addition, SSAs may prevent 
the enterochromaffin-like cell hyperplasia or the devel-
opment of gastric type 2 NETs, which are related to 
hypergastrinemia [94]. IFN-α (5 × 106 IU/day) improved 
clinical symptoms caused by hypergastrinemia only in 
stabilized tumors. Unfortunately, side effects frequently 
require dose reduction or drug withdrawal [85]. Further-
more, PRRT with radiolabeled beta emitting SSAs can 
lead to long-lasting (> 1 year) tumor responses in a very 
high number of patients and also leads to symptomatic 
improvement [50, 95].
2.5  Vasoactive Intestinal Polypeptide (VIP)oma, 
Somatostatinoma
Functioning NETs that release vasoactive intestinal poly-
peptide (VIP) have an incidence of 1:10 million persons/
year. These tumors produce watery diarrhea, accompanied 
by severe hypokalemia, and hypo- or achlorhydria. In con-
trast, somatostatinomas may be asymptomatic or present 
with diabetes mellitus, cholelithiasis, weight loss, steator-
rhea, and diarrhea; their annual incidence is 1 in 40 million 
[96–98]. Initial treatment in VIPomas and symptomatic 
somatostatinomas is based on fluid loss replacement and 
electrolyte correction. Octreotide and lanreotide may con-
trol symptoms in the majority of patients [96, 99, 100], but 
in refractory cases glucocorticoids may be used as adju-
vant therapy [96]. Equivalent to other pancreatic NETs, 
molecular targeted therapy and PRRT may be useful in 
metastasized cases, but due to their low incidence, sub-
group analyses on the efficacy of these novel therapeutic 
alternatives in these NETs are not available [13, 80–82, 
101, 102].
2.6  Ectopic Hormone Production Syndromes
Ectopic hormone production is rare in NETs. Among them, 
adrenocorticotropic hormone (ACTH)-producing tumors are 
most commonly observed. Ectopic release of other peptides 
includes corticotropin-releasing hormone (CRH), growth 
hormone-releasing hormone (GHRH), antidiuretic hormone, 
parathyroid hormone-related peptide (PTHrP), and gonado-
tropins [103–105]. The aim of treatment of these patients 
includes symptomatic long-term control, tumor stabilization 
or reduction, and prolongation of (progression-free) survival 
[104].
2.6.1  Adrenocorticotropic Hormone (ACTH)
The ectopic ACTH syndrome (EAS) causes approximately 
10% of all cases of Cushing syndrome [106, 107]; clinical 
evolution is usually faster and characterized by mineralo-
corticoid effects (hypertension, hypokalemia, and edema), 
thromboembolic disease, and opportunistic infections [108]. 
Curative surgery is the primary treatment option but is often 
not possible [106, 109]. EAS can result in a critical con-
dition for which aggressive medical therapy or life-saving 
bilateral adrenalectomy is necessary [108]. Medical treat-
ment options for EAS include: (1) Tumor-directed drugs 
including somatostatin analogs (octreotide, pasireotide) 
and dopamine agonists that decrease tumoral ACTH secre-
tion [108, 110–113]. The identification of SSTR expression 
in the tumor using radiolabeled somatostatin analogs may 
also help to identify suitable patients who might benefit 
from PRRT [95, 110, 114]. In addition, the tyrosine kinase 
inhibitors vandetanib and sorafenib may have antisecretory 
effects in selected cases with EAS [115, 116]. (2) Steroid 
synthesis inhibitors, which directly suppress adrenal cortisol 
production. In this sense, a combination of ketoconazole, 
metyrapone, and mitotane was shown to be effective in criti-
cally ill patients with EAS [117]. Additionally, the anesthetic 
drug etomidate can also rapidly suppress cortisol levels in an 
ICU setting [118]. (3) Glucocorticoid receptor antagonists. 
Mifepristone has a short onset of action and was shown to 
reverse morbidity of EAS in several cases [119].
2.6.2  Growth Hormone‑Releasing Hormone (GHRH)
Ectopic GHRH production is predominantly encountered in 
patients with lung carcinoids [120]. Although some patients 
have evident clinical features of increased GH production, 
GHRH-staining may be positive in asymptomatic NET 
patients [121]. SSAs are widely used for the treatment of 
acromegaly due to GH-secreting pituitary adenomas, but 
medical treatment of acromegaly due to ectopic GHRH 
secretion is less well explored [122]. SSAs (octreotide and 
lanreotide) lower ectopic tumoral production of GHRH with 
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a subsequent decrease in circulating GH and insulin-like 
growth factor-1 (IGF-1) levels [123, 124]. In some cases, 
tumor control and clinical improvement may be achieved, 
but circulating GHRH may continue to be elevated [125].
2.6.3  Parathyroid Hormone‑Related Protein (PTHrp)
PTHrp production is predominantly associated with PNETs; 
overall survival in patients with PTHrp production is 
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significantly shorter compared to pNET patients with nor-
mocalcemia [104, 126]. In PTHrp-producing NETs, hyper-
calcemia needs to be controlled. Treatment options for 
hypercalcemia include intravenous isotonic saline (corrects 
volume depletion), bisphosphonates (interfere with the oste-
oclast-mediated bone resorption), and denosumab (reduces 
the formation, function, and survival of osteoclasts via the 
receptor activator of nuclear factor κB (RANK) pathway) 
[104, 127, 128]. SSAs may help to improve symptom control 
but might be insufficient in patients with tumor progression 
[88, 104]. Tumor stabilization with parallel calcium control 
has been described in three of five patients after receiving 
PRRT with 177Lu-DOTATATE [104].
3  Control of Tumor Growth
According to the latest analysis of the SEER database, 
27.4% of NETs have distant metastases at diagnosis and 20% 
have regional infiltration [6]. Survival in NETs is related 
to tumor localization, tumor load, and grading, and these 
factors should be considered when selecting the appropri-
ate medical treatment. Current and promising novel medical 
options for tumor growth control in NETs are presented in 
Fig. 2. The landmark clinical trials proving efficacy of the 
current medical options for tumor growth control in NETs 
are depicted in Table 1. Additionally, some current clini-
cal trials for tumor growth control in NETs are depicted in 
Table 2.
3.1  Somatostatin Analogs
The antiproliferative effect of SSAs mostly depends on 
SSTR tumor expression, although indirect antitumor effects 
have been described as well [129]. SSAs may inhibit the 
cell cycle and increase apoptosis, and indirect effects may 
include immuno-modulation, antiangiogenic effects, and 
growth factor inhibition [9, 12, 100]. Octreotide and lan-
reotide bind preferably to SSTR2, and pasireotide has high 
binding affinity to multiple SSTR, particularly SSTR5 
(Fig. 1) [130]. Long-acting preparations of octreotide and 
lanreotide monthly are usually used for disease stabilization 
in NETs [9, 131]. The antiproliferative effect of SSAs in 
NETs was initially evaluated in the PROMID study [132]. 
In this phase IIIB study, 85 well-differentiated metastatic 
midgut NETs were included. Patients were randomized to 
receive placebo or octreotide-LAR 30 mg every 4 weeks. A 
difference of 8.3 months in tumor progression was observed 
after comparing the octreotide and the placebo groups. 
Stable disease after 6 months was observed in 66.7% of 
patients treated with octreotide-LAR compared to 37.2% in 
the placebo group [132]. Despite the initial good response 
to octreotide LAR, the results from the long-term survival 
analysis revealed that overall survival (OS) was not signifi-
cantly different in the placebo and the octreotide groups 
[133]. Interestingly, patients with resected primary tumor 
and/or lower liver tumor load benefitted more from the initial 
administration of octreotide [132, 133].
Similar to the PROMID study, the CLARINET study 
revealed that lanreotide (120 mg every 28 days) increased 
PFS of patients with metastatic well- and moderate-differ-
entiated GEP NETs when compared to placebo (PFS rate 
of 65.1% in the lanreotide group and 33% in the placebo 
group) [134]. Usually SSAs induce tumor stabilization, but 
in selected cases SSAs can cause tumor shrinkage, possi-
bly due to their effects on the perfusion of liver metastases 
[135]. Representative images of tumor shrinkage in response 
to lanreotide are depicted in Fig. 3a. According to the cur-
rent clinical guidelines, SSAs are indicated in grade 1 (G1) 
non-functional NETs after progression without previous 
treatment (watch and wait strategy), in G1 NETs with high 
tumor load, or in non-functional grade 2 (G2) NETs with 
SSTR expression [23]. Because G1 and G2 NETs can ini-
tially show a stable disease course without treatment, mark-
ers are needed that can identify those patients in whom early 
treatment should be evaluated versus those patients in whom 
a wait-and-see strategy should be considered initially.
Fig. 2  Current and future medical options for tumor control in neu-
roendocrine tumors. Current therapeutic options are presented in 
blue, possible novel therapeutic options are presented in red. SSAs 
and PRRT: increase apoptosis by activating the protein tyrosine 
phosphatase SHP1; decrease cell proliferation and survival through 
the mitogen-activated protein kinase (MAPK) and cyclic adenosine 
monophosphate (cAMP); and inhibit the signaling of the insulin-like 
growth factor receptor type 1 (IGFR-1); additionally, PRRT produces 
DNA double strand breaks induced by β-irradiation, consequently 
leading to apoptosis. Sunitinib is a multikinase inhibitor that modu-
lates the phosphoinositate-3-kinase/Akt pathway (it blocks the vas-
cular endothelial growth factor receptors (VEGFR) 1-3, the platelet-
derived growth factor receptors (PDGFR) α and β, and the epidermal 
growth factor receptor (EGFR)). Everolimus decreases tumor cell 
proliferation, metabolism, survival, and angiogenesis through the 
mammalian target of rapamycin complex-1. The indirect inhibition 
of mTOR through the phosphoinositate-3-kinase/Akt produced by 
the SSAs seems to increase sensitivity to mTOR inhibition. Multi-
receptor chimeras may bind SSTR and D2R, and may enhance the 
signaling of the cAMP and JNK pathways; induced SST2R inter-
nalization and SST2R/D2R heterodimerisation interference have also 
been hypothesized. The interaction between some receptors expressed 
on the surface of cytotoxic T-cells (PD-1, CTLA-4) with ligands 
expressed on the tumor cells (PDL-1, B7-1/B7-2) downregulates the 
immune response to tumor cells; novel drugs that target these specific 
immune checkpoints inhibit this interaction allowing the immune sys-
tem to maximize an efficient antitumor response. SSAs somatostatin 
analogs, PRRT peptide receptor radionuclide therapy, IGF-1R insulin-
growth factor receptor type 1, VEGFR vascular endothelial growth 
factor, EGFR epidermal growth factor receptor, PDGFR platelet-
derived growth factor receptors, mTOR mammalian Target of Rapa-
mycin, CTL4 cytotoxic T-lymphocyte antigen-4, PDL-1 Programmed 
death-ligand 1
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In addition, increased doses of SSAs seem to exert an 
apoptotic effect, which is not achieved with the standard 
doses [136]. These effects have been described in patients 
showing disease progression under regularly dosed lanreo-
tide and octreotide [35, 137]. Currently, the CLARINET 
FORTE study is evaluating the safety and antitumor effect 
of lanreotide 120 mg given every 14 days in patients with 
pancreatic or midgut NETs with progressive disease under 
the same dose used every 4 weeks for at least 6 months 
(NCT02651987).
Pasireotide has also been studied in NETs, in which pasir-
eotide concentrations correlated with tumor shrinkage in a 
non-significant manner [138]. Other studies have reported 
predominantly disease stabilization (60%) in treatment-naïve 
patients with grade 1–2 NETs, but also partial response (4%) 
and disease progression (36%) have been described [139]. 
Additionally, pasireotide-LAR has been compared to octre-
otide-LAR in patients with metastatic NETs and carcinoid 
symptoms. In these patients, pasireotide tended to increase 
the tumor control rate after 6 months and was associated 
with a longer PFS [43]. In the prospective phase II LUNA 
study in advanced (unresectable or metastatic), progres-
sive, well-differentiated carcinoid tumors of the lung or 
thymus, pasireotide LAR treatment resulted in an objective 
tumor response in 39% of patients [140]. In the randomized, 
open-label, phase II COOPERATE-2 study of everolimus in 
combination with pasireotide LAR or everolimus alone in 
advanced, well-differentiated, progressive pancreatic neu-
roendocrine tumors, the addition of pasireotide to everoli-
mus was not associated with improvement in PFS compared 
with everolimus alone [46]. Further investigation to evaluate 
the applicability of pasireotide alone or in combination with 
other therapies is required.
SSAs are generally well tolerated; common adverse 
events include nausea, abdominal pain, headache, dizzi-
ness, fatigue, and back pain; hematopoietic complications 
and bile stones have been also described [141]. These 
events may begin shortly after the first administration of 
the drug and may decrease progressively over the subse-
quent weeks as treatment continues [88]. In the PROMID 
study five patients stopped treatment due to an adverse 
event. In the CLARINET study, 25 of 101 patients had 
serious adverse events but only three were related to the 
study treatment [134].
3.2  Interferon‑Alpha
Interferon-alpha has antiproliferative, pro-apoptotic, 
cytotoxic/cytostatic, and immunomodulatory effects in 
NETs [142, 143]. It has been considered as a second-line 
therapeutic option in progressive NETs under SSAs [23, 
144]. Several studies have failed to show a significant SS
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Table 2  Registered clinical trials for tumor growth control medical therapies in NETs
Drug Study characteristics Primary outcome/ClinicalTrials.gov Identifier
Somatostatin analogs
 Lanreotide (CLARINET FORTE) Open-label single-group clinical trial for evalu-
ating the efficacy and safety of lanreotide 
120 mg every 14 days in well-differentiated, 
metastatic or locally advanced, unresectable 
pancreatic or midgut NETs with radiological 
progression with lanreotide 120 mg every 
28 days
PFS (102 weeks)/NCT02651987
 177Lu-DOTA0-Tyr3-Octreotate (NETTER-1) Multi-center, randomized, phase III study 
comparing 177Lu-DOTA0-Tyr3-Octreotate to 
Octreotide LAR in patients with inoperable, 
progressive, somatostatin receptor positive 
midgut carcinoid tumors
PFS, OS data is pending/NCT02651987
Kinase inhibitors
 Sulfatinib Randomized, multicenter phase III study to 
evaluate the efficacy and safety of sulfatinib 
(angio-immunokinase inhibitor targeting 
VEGFR, FGFR1, and CSF-1R kinases) vs. 
placebo in advanced PNETs
PFS (7 months after the last patient enrolled)/
NCT02589821
 Sulfatinib Randomized, double-blind, multicenter phase 
III study to evaluate the efficacy and safety of 
sulfatinib vs. placebo in advanced PNETs
PFS (9 months after the last patient enrolled)/
NCT02588170
Radionuclide therapy
 177Lu-PRRT vs. 177Lu-PRRT plus capecit-
abine
Open-label phase II study to compare the 
efficacy of 177Lu-PRRT vs. 177Lu-PRRT plus 
capecitabine in SSTR and 18-FDG PET/CT 
positive, G1-G2-G3 GEP-NETs
PFS (72 months)/NCT02736448
 177Lu-Octreotate -CAPTEM vs. (i) CAPTEM 
and (ii) 177Lu-Octreotate
Two parallel phase II randomized open-label 
trials of PRRT with 177Lu-Octreotate and 
CAPTEM (i) vs. CAPTEM alone in the treat-
ment of low to intermediate grade PNETs (ii) 
vs. 177Lu-Octreotate alone in the treatment of 
low to intermediate grade midgut NETs
PFS (12 months in PNETs and 24 months in 
midgut NETs)/NCT02358356
 177Lu-edotreotide vs. Everolimus Prospective, randomized, controlled, open-
label, multicenter phase III study to evalu-
ate the efficacy and safety of PRRT with 
177Lu-edotreotide compared to everolimus in 
GEP-NETs
PFS assessed up to 24 months/NCT03049189
 177Lu-DOTA0-Tyr3-Octreotate vs. sunitinib Open-label randomized phase II antitumor 
efficacy of PRRT with 177Lu-DOTA0-Tyr3-
Octreotate vs. sunitinib in unresectable 
progressive well-differentiated PNETs
PFS (12 months)/NCT02230176
mTOR inhibitors
 Everolimus and LEE011 (Ribociclib) Open-label study to evaluate the efficacy and 
safety of the combination LEE011 (inhibi-
tor of cyclin D1/CDK4 and CDK6 pathway) 
300 mg once daily for 3 weeks (4th week 
off) and everolimus 2.5 mg daily in foregut 
WDNETs
PFS (2 years)/NCT03070301
 Everolimus and TMZ Open-label study to evaluate everolimus and 
temozolomide as first-line treatment in 
advanced NEC with a Ki67 of 20–55%
Disease control rate/NCT02248012
 Everolimus and bevacizumab Randomized phase II study of everolimus alone 
vs. combined with bevacizumab in patients 
with PNETs (currently active, not recruiting)
PFS (up to 3 years)/NCT01229943
 Everolimus and cisplatinum Open-label phase II study of cisplatinum and 
everolimus in metastatic or unresectable NEC 
of extrapulmonary origin
Disease control rate/NCT02695459
Targeted Systemic Treatment of Neuroendocrine Tumors
additional effect of interferon-alpha on top of that of 
SSAs [32, 44, 145]. Tumor response rates of about 10% 
have been reported [146] and its efficacy is similar to 
other agents including bevacizumab when combined with 
SSAs [147]. Unfortunately, several adverse effects have 
been described; a pegylated formulation seems to be asso-
ciated with decreased side effects, and its combination 
with octreotide seems to be better tolerated [146, 148]. 
Despite this, the availability of novel therapeutic options 
with higher efficacy and lower side effects limit the appli-
cability of this drug for tumor control [149].
3.3  Peptide Receptor Radionuclide Therapy (PRRT)
PRRT with a somatostatin analog allows targeted delivery 
of radionuclides to tumor cells expressing high levels of 
SSTR. Radiolabeled SSAs consist of a radionuclide isotope 
(90Y or 177Lu), a carrier molecule (generally octreotide or 
octreotate), and a chelator (usually DOTA: tetra-azacyclodo-
decane-tetra-acetic acid or DTPA: diethylenetriamine penta-
acetic acid) [150]. 177Lu-DOTA-octreotate or 177Lu-Dota-
tate is the most studied molecule. The 177Lu radionuclide 
is characterized by the emission of β-rays, which have an 
intermediate tissue penetration, and γ-rays, which are used 
for monitoring and dosimetry by post-therapy scintigraphy 
[151].
Treatment response is directly related to the expression 
of SSTR in the tumor, making it a predictive marker of 
response [152], although tissue SSTR immunohistochem-
istry has no additional value to SSTR scintigraphy in pre-
dicting tumor response to PRRT [153]. For PRRT, patients 
should have a positive NET histology and a positive SSTR 
scintigraphy with 111In-DTPA-octreotide (OctreoScan; 
lesion uptake equal or greater than the liver uptake) or a 
positive 68Ga-DOTA-SSA PET-CT [154]. In 443 bronchial 
and GEP NET patients PRRT induced an objective tumor 
response (complete or partial) in 39% and stable disease in 
43% of patients. In this cohort PFS was 29 months (range 
26–33) and OS 63 months (range 55–72) [155]. Tumor 
response may differ according to the primary tumor locali-
zation and tumor load [156]. OS is also different in NETs of 
different localizations (pancreas 71 months (95% CI 56–86), 
midgut 60  months (95% CI 52–68))[155]. In contrast, 
response rates are lower in patients with larger tumor load 
and higher liver infiltration [157]. A representative example 
of tumor response to PRRT is depicted in Fig. 3b.
An OS of 27–95 months and a PFS of 16–29 months 
have been reported in NET patients receiving treatment 
with 90Y-DOTATOC [158–160], but regimens employing 
NETs neuroendocrine tumors, PRRT peptide receptor radionuclide therapy, CAPTEM Capecitabine/temozolomide, PFS progression-free sur-
vival, OS overall survival, VEGFR vascular endothelial growth factor, FGFR fibroblast growth factor receptor, CSF-1R colony-stimulating factor 
1 receptor, PNETs pancreatic neuroendocrine tumors, PRRT peptide receptor radionuclide therapy, 18-FDG PET/CT18-fluorodeoxiglucose pos-
itron emission tomography–computed tomography, GEP-NET gastroenteropancreatic neuroendocrine tumors, CDK cyclin-dependent kinases, 
WDNETs well-differentiated neuroendocrine tumors, TMZ temozolomide, NEC neuroendocrine carcinoma, PDGFR platelet-derived growth fac-
tor receptor, PD1 programmed death-1, CTLA-4 cytotoxic T-lymphocyte-associated protein 4
Table 2  (continued)
Drug Study characteristics Primary outcome/ClinicalTrials.gov Identifier
Immunotherapy
 Pembrolizumab Open-label phase II study of monotherapy with 
pembrolizumab (humanized anti-PD-1 mono-
clonal antibody) in patients with metastatic 
high-grade NETs who have failed platinum-
based chemotherapy
Objective response rate/NCT02939651
 PDR001 Open-label phase II study to evaluate PDR001 
(high-affinity, ligand-blocking, humanized 
IgG4 antibody directed against PD-1) in 
advanced or metastatic, well-differentiated, 
non-functional, thoracic and GEP-NETs or 
GEP-NECs
Overall response rate/NCT02955069
 Durvalumab and tremelimumab Multicenter open-label phase II study to evalu-
ate the combination therapy between dur-
valumab (MEDI4736; humanized antibody 
against PD-1) and tremelimumab (CTLA-4 
inhibitor) in advanced/metastatic, grade 1/2 
(G1/G2) lung and GEP-NETs, and grade 3 
(G3) GEP- tumors or of unknown primary 
site after progression to previous therapies
Clinical benefit rate/NCT03095274
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90Y have been associated with an increased incidence of 
renal toxicity. Available studies are difficult to compare 
since the inclusion criteria and basal characteristics of the 
included patients differ considerably [150]. Single-center 
studies evaluating 177Lu-Dotatate reported a median OS of 
46 months, median time to progression of 36–40 months, 
and PFS of 33–36 months [82, 161–163]. Imaging response 
rates of 18–44% (by RECIST criteria) and improvement in 
quality of life have also been reported [164, 165]. The piv-
otal phase III NETTER-1 trial for the first time evaluated the 
efficacy of PRRT with 177Lu-DOTATATE in a multicenter, 
randomized clinical trial. This study included 229 patients 
with well-differentiated, metastatic midgut NETs that were 
progressive on a standard dose of long-acting SSA. Patients 
were randomized to receive four cycles of PRRT with 177Lu-
Dotatate or a double dose (60 mg/28 days) of octreotide 
LAR. The primary outcome was an increase in PFS (median 
not reached vs. 8.4 months) in favor of patients treated with 
PRRT. This study also reported a 79% reduction in the risk 
of progression or death compared to octreotide and increased 
overall response rate (ORR) in the PRRT group (18%) com-
pared to 3% in the control group [166]. Despite PRRT being 
a promising treatment in GEP-NETs, the application in lung 
NETs may be limited due to a low expression of SSTR in 
some cases, especially in some atypical lung carcinoids; not-
withstanding, ORR of 15%, disease stabilization of 47%, 
and OS of 52 months (95% CI 49–55) have been reported 
[155, 167].
In the case of tumor progression after an initial good 
response, retreatment with PRRT represents an alterna-
tive. In this sense, disease control rates of 70–85% have 
been reported, but tumor response is limited [168, 169]. 
177Lu-DOTATATE has also been evaluated with radiosen-
sitizing agents; its use in combination with 5-fluorouracil, 
Fig. 3  Peptide receptor radionuclide therapy in neuroendocrine 
tumors (NETs). a CT imaging of a pancreas neuroendocrine tumor 
grade 2 with lymphatic and liver metastasis (segment 6); in this case, 
four cycles of peptide receptor radionuclide therapy (cumulative dose 
30 Gbq) was administered resulting in decreased size of the primary 
tumor (b). After 6  years of partial response and stable disease, the 
primary tumor increased in size accompanied by new liver and mes-
enteric metastasis (c). Because of an initial good treatment response, 
two cycles of PRRT (14.9 GBq) were administered, and a decreased 
size of primary tumor and liver metastasis were observed (d). Images 
are of an NET patient evaluated in the ENETS Center of Excellence 
Erasmus MC, Rotterdam. Informed consent was provided
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capecitabine, or temozolomide may increase the response 
rate (ORR 24–38%), but toxicity should still be evaluated 
[170–172]. Similar ORR has been reported when combined 
with everolimus [173]. Some case reports and series have 
suggested the use of pre-operative PRRT for downstaging 
NETs [174–176], but further investigation is still required on 
the efficacy of neoadjuvant PRRT in patients with initially 
unresectable NETs.
PRRT is generally well tolerated. Nausea, fatigue, or 
abdominal pain may occur; they have been related to the 
amino acid infusion given for kidney protection and are self-
limiting within 24 h [150]. Other adverse effects include 
neutropenia (1%), thrombocytopenia (2%), and lymphopenia 
(9%) [166]. Increased serum levels of liver enzymes and 
chromogranin A during or directly after therapy may be 
related to radiation-induced inflammation or progressive dis-
ease, and follow-up and repeated measurements are required 
[177]. Long-term side effects of PRRT may include renal 
failure and acute leukemia or myelodysplastic syndrome in 
1–2% of cases [150, 155, 156]. Some clinical conditions 
increase PRRT toxicity (hypertension, diabetes, and renal 
or bone marrow impairment).
Currently several clinical trials aim to further optimize 
PRRT by evaluating the efficacy of PRRT alone or in com-
bination with chemotherapeutic agents (capecitabine or 
capecitabine/temozolomide) in patients with undifferentiated 
NETs (NCT02358356). Novel radioligands include SSTR 
antagonists, the combination of PRRT with immunotherapy, 
and the use of α emitters [150]. SSTR antagonists may have 
higher tumor uptake, longer retention, and decreased radio-
activity in healthy organs compared to 177Lu-Dotatate [150, 
178]. Alpha emitters, such as 213Bi, can induce more DNA 
damage; however, toxicity is a problem for alpha-emitting 
radionuclides, which limits their applicability in the clinical 
practice. Additionally, other pharmaceutical agents (olapa-
rib) could sensitize NET cells to PRRT according to in vitro 
models [179]. Predictive response models are also under 
study. For instance, NET blood gene expression assays have 
been evaluated in recent years [180]; these results, in com-
bination with tumor grade, may help to predict the response 
to PRRT [181]. Recently a binary predictive quotient was 
described based on the use of NET blood gene transcripts 
combined with Ki67, and this quotient predicted 100% of 
responders and 84% of non-responders with an accuracy 
of 95% [182]. These data should, however, be validated in 
independent cohorts. Soon the results of the COMPETE 
study will be available. The aim of this multicenter phase III 
study is to evaluate the efficacy and safety of PRRT (177Lu-
Edotreotide), compared to everolimus, in progressive GEP-
NETs with positive expression of SSTR (NCT03049189). 
This comparison aims to provide information on the treat-
ment sequence that should be followed in progressive NETs 
under SSAs. Finally, the development of new radiopeptides 
targeting other receptors (e.g., gastrin-releasing peptide) 
may also represent a therapeutic option in the future [183].
3.4  Everolimus
The mTOR pathway plays an important role in the regula-
tion of cell proliferation in NETs [15]. The efficacy of the 
PI3 K/AKT/mTOR inhibitor everolimus in well-differenti-
ated NETs has been shown in several clinical trials [23]. In 
the phase III RADIANT 3 trial, everolimus was compared 
to placebo in patients with low or intermediate-grade PNETs 
with radiologic progression within the previous year. PFS 
was longer in the everolimus group. Additionally, only a 
non-significant 6.3 months OS benefit was observed, and 
this last result may be related to the switch of patients from 
the placebo group (85% experienced progressive disease) 
to the open-label everolimus group [184]. Despite this, the 
effect of everolimus on PFS and OS was independent of 
the prior use of chemotherapy or SSAs [184–186]. A simi-
lar study was conducted in gastrointestinal and lung NETs 
(RADIANT 4), where increased PFS (11 vs. 3.9 months) 
and higher disease control rate (81% vs. 64%) in favor of 
the everolimus-treated group were reported [187]. However, 
although everolimus is considered a safe drug, treatment 
can be accompanied by grade 3 and 4 drug-related adverse 
events (diarrhea, infections, anemia, fatigue, hyperglycemia) 
[187], which may limit treatment tolerance and consequently 
patient adherence. Importantly, the RADIANT 4 study, as 
the previous ones, failed to demonstrate statistically sig-
nificant improvements in OS [187], which should be taken 
into account especially in those patients with poor treatment 
tolerance.
The combination of everolimus and octreotide LAR has 
also been compared to octreotide LAR alone in function-
ing GEP- and lung NETs (carcinoid syndrome; phase III 
RADIANT 2). PFS was 5.1 months longer in the combina-
tion group but the hazard ratio (HR) was not statistically 
significant between the two groups [188]. In lung NETs, 
2.4-fold longer PFS, 28% reduction in the risk of disease 
progression, and a twofold increase in the proportion of 
patients with tumor shrinkage were reported in the combina-
tion arm [189]. In colorectal NETs similar results have been 
described, including a fourfold prolonged PFS and increased 
frequency of tumor shrinkage (67% vs. 37%) [190]. As 
opposed to the positive results of combination therapy with 
everolimus and octreotide LAR, the combination of everoli-
mus with pasireotide did not improve PFS or OS when 
compared to everolimus alone in progressive PNETs [46]. 
In contrast, in lung and thymic NETs the combination of 
pasireotide (60 mg every 28 days) with everolimus increased 
the progression-free rate (58.5%) when compared to pasire-
otide (39%) or everolimus (33.3%) at 9 months (phase II 
LUNA trial). Importantly, 27% of patients discontinued the 
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treatment due to progressive disease or adverse events [191]. 
A synergistic effect of epidermal growth factor receptor 
(EGFR) and mTOR pathways inhibitors has been suggested 
in bronchial carcinoids [192]. For this reason the combina-
tion with sunitinib/erlonitib is currently under study.
Everolimus is considered as first-line therapy in progres-
sive atypical lung carcinoids, SSTR-negative lung NETs, 
and in well-differentiated midgut SSTR-negative NETs [23]. 
Currently several studies are evaluating the combination of 
everolimus with other therapies including chemotherapeu-
tic agents, SSAs, molecular targeted therapies, radiotherapy, 
and PRRT.
3.5  Sunitinib
Because NETs are generally hypervascularized tumors, 
treatment with antiangiogenic drugs seems a rational 
approach. Sunitinib is as an oral multi-targeted tyrosine 
kinase inhibitor (TKI) that inhibits multiple angiogenic fac-
tors including the vascular endothelial growth factor recep-
tors 1-3 (VEGFR), the stem-cell factor [SCF] receptor, and 
the platelet-derived growth factor receptors [193]. Initially in 
a two-cohort phase II study, sunitinib, administered 50 mg/
day orally for 4 weeks followed by 2 weeks off treatment, 
reported poor response rates in PNETs and carcinoids 
(16.7% and 2.4%, respectively) [194]. In contrast, a pla-
cebo-controlled phase III study in progressive PNETs (SUN 
1111 trial) reported increased PFS in the sunitinib group 
(11.4 months, hazard ratio for progression or death, 0.42; 
95% CI 0.26–0.66) compared to placebo (5.5 months), and 
resulted in study discontinuation due to a higher incidence 
of adverse events and deaths in the placebo group [80]. 
Recently a retrospective imaging analysis of 171 patients 
with well-differentiated metastatic and/or progressive 
PNETs was performed. Patients received 37.5 mg sunitinib 
daily or placebo. PFS was increased in the sunitinib group 
(12.6 months) compared to placebo (5.8 months). 5 years 
after the study closure, median OS was 38.6 (25.6–56.4) 
months for sunitinib and 29.1 (16.4–36.8) months for pla-
cebo (HR, 0.73; 95% CI 0.50–1.06; p = 0.094). In this study 
69% of patients randomized for placebo crossed over to suni-
tinib, probably affecting the significance of the OS [195], as 
has been reported in previous studies [196]. As for everoli-
mus, significant improvement in OS has not been reported 
yet.
Sunitinib is associated with several adverse events includ-
ing hypertension, diarrhea, nausea, vomiting, asthenia, skin 
toxicity, and fatigue [80]. Importantly, drug-related adverse 
events with sunitinib are increased threefold as compared 
with placebo [193], but fewer grade 3–4 toxicities are 
observed when compared with chemotherapeutic agents 
[197]. Dose reduction or temporary interruption of therapy 
may resolve the adverse clinical situation [193]. Importantly, 
no differences in the quality-of-life index have been reported 
when compared to placebo [193].
Sunitinib dose reduction should be considered when 
co-administered with strong CYP3A4 inhibitors, includ-
ing ketoconazole, ritonavir, itraconazole, erythromycin, or 
clarithromycin. In contrast, dose should be increased when 
administered with CYP3A4 inducers, such as dexametha-
sone, phenytoin, carbamazepine, or phenobarbital [193].
Sunitinib is currently being compared to other treatment 
options in NETs including everolimus and PRRT. Current 
therapeutic options and a possible therapeutic sequence are 
depicted in Fig. 4.
3.6  Other Treatments
Other TKIs and antiangiogenic drugs have been evaluated 
in NET patients in open-label phase II studies (Table 2). 
Importantly, these therapies have been considered as promis-
ing options in NETs, but further studies are still required. In 
this sense, despite promising phase II data of bevacizumab 
administration in patients with gastrointestinal NETs, a 
phase III trial failed to show superior efficacy of bevaci-
zumab compared to interferon alfa-2b [147]. The combi-
nation therapy of sorafenib and bevacizumab can induce 
antitumoral response, but was accompanied by an unfavora-
ble safety outcome in a phase II study [198]. In contrast, 
the combination of bevacizumab with everolimus showed 
improved tumor response rates but no significant effect on 
PFS [199]; even more, the combination of everolimus with 
sorafenib reported dose-limiting toxicities [200]. Biochemi-
cal and radiological response has been described in PNETs 
treated with pazopanib [201], but further evaluation is still 
required; importantly, results of randomized trials are still 
pending and its combination with temozolomide is currently 
under evaluation (NCT01465659).
Systemic chemotherapy is indicated for the poorly dif-
ferentiated grade 3 neuroendocrine carcinomas. Chemother-
apy is not discussed in this review, but some publications 
describe the significant advances in this field in the last years 
[16, 202–204].
4  Future Directions
The comprehensive evaluation of signaling pathways regu-
lating cell proliferation involved in NET development and 
progression has opened new perspectives for the medical 
treatment of these tumors. Current clinical trials for tumor 
growth control including novel drugs, treatment compari-
sons, and combinations are summarized in Table 2.
mTOR inhibitors and TKIs are the most representative 
examples, but other novel pathway-directed therapeutic 
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compounds are also currently being evaluated in (pre-)clini-
cal studies [205]. Current clinical trials include head-to-head 
comparisons between novel therapies (PRRT vs. everoli-
mus/sunitinib/capecitabine-temozolomide) and combina-
tion therapies (everolimus with bevacizumab/cisplatinum/
temozolomide; PRRT with capecitabine-temozolomide). 
Additionally, trials that compare treatment sequences are 
also recruiting patients (sequencing of streptozocin-5-FU 
followed by everolimus vs. the reverse order of treatment, 
NCT02246127). These results may help to improve the 
sequence of therapy in NET patients.
Other examples of potential new treatment options 
include immunotherapy and somatostatin-dopamine multi-
receptor chimeras. The mechanisms of action of immune 
checkpoint inhibitors and multi-receptor chimeras are also 
depicted in Fig. 2.
Immune checkpoint inhibitors have rapidly advanced 
and improved the management of several tumors in the last 
years [206, 207]. Programmed death-ligand 1 (PD-L1) is 
expressed on several cancer cells and interacts with PD1, 
which is expressed on T cells. This ligand-receptor inter-
action inhibits T cells and blocks their antitumor immune 
response [208, 209]. PD1/PDL1 expression has been 
demonstrated in several cancers [210–212]. Studies testing 
anti-PD-L1 or anti-PD1 agents have shown promising results 
in, for instance, small-cell lung cancer (SCLC) and mela-
noma [209]. The expression of PD-L1 was demonstrated 
in GEP- and lung (large cell neuroendocrine carcinoma) 
NETs using immunohistochemistry and qPCR [208, 213, 
214]. Additionally, an inverse relation between PD-L1 and 
angiogenesis/hypoxia factors (vascular endotelial growth 
factor-A, hypoxia inducible factor 1a) has been described 
[215]. Importantly, PD-L1 has been associated with clini-
cal variables in lung and GEP-NETs, including histological 
type, tumor grade, and survival [208, 216], which have not 
been described in midgut NETs [214]. Observations that the 
expression levels of PD-1 and PD-L1 were an independent 
survival prognostic factor in NETs [216] should be subjected 
to further study [214].
The use of cytotoxic T-lymphocyte antigen-4 (CTL4) 
blockers has also been reported in SCLC [217]. CTL4 is a 
critical negative regulator of the antitumor T-cell response, 
and its inhibition has encouraging effects in SCLC and 
melanoma [217, 218]. Additionally, the efficacy of immune 
checkpoint inhibitors may be affected by the presence of 
tumor infiltrating lymphocytes (TILs) [219]. TILs have been 
Lung NETs Pancreas NETs Midgut NETs
Grade I-II, 
non-resectable tumor
SSTR expression 
yes no
Long acng SSA (octreode + 
or lanreode + +) every 28 
days
Progressive 
 disease 
Increase SSA dose + +
Increase SSA injecon frequency + +
PRRT** + +
Switch SSA + +
Add on Interferon-alpha + 
Interferon-alpha + 
Everolimus + + 
Suninib + 
Cytotoxic chemotherapy*** + 
Progressive  
disease 
Clinical trial + +
Chemotherapy + +
Watchful waing 
If SSTR posive: SSA*
Everolimus 
If SSTR posive: SSA
If SSTR posive: PRRT*
Clinical trial
Progressive 
 disease 
Progressive 
 disease 
Fig. 4  Treatment algorithms for tumor control in neuroendocrine 
tumors (NETs). Summary of current medical strategies for tumor 
control in NETs according to the primary tumor site. Legend: Blue, 
red and green colors represent lung, pancreas and midgut NETs 
respectively. SSTR somatostatin receptor expression, SSA somato-
statin analog, PRRT peptide receptor radionuclide therapy. *Not 
registered for this indication, **PRRT has been approved in Europe 
for midgut NETs and in the USA for midgut and pancreatic NETs, 
***streptozocin/5-fluorouracil or streptozocin/doxorubicin; temozo-
lomide/capecitabine as an alternative regimen
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suggested as a survival predictor for intermediate grade (Ki 
67 2–20%) PNETs, since increased recurrence-free survival 
was observed in patients with higher TIL density [219]. The 
modulation of TILs density may also be a promising thera-
peutic option in the future. Despite immunotherapy hav-
ing an important role in the management of other types of 
cancer, the effect on well-differentiated NETs according to 
preliminary data seems to be limited, although it may rep-
resent an option for G3NETs/NECs, which needs further 
investigation [220].
Multi-receptor interaction has been suggested as an effi-
cacious and selective therapeutic strategy for enhancing the 
effects of somatostatin [221]. The presence of hetero-dimers 
has been described among SSTRs and between SSTRs and 
other receptor families, including dopamine receptors, espe-
cially the dopamine receptor subtype 2 (D2R) [222, 223]. 
Based on this, some structural chimeric molecules that com-
bine elements of SSAs and dopamine analogs (DA) have 
been developed [221]. In vitro studies using a pancreatic 
NET cell model revealed inhibitory properties of chimeras 
on hormone secretion without affecting cell proliferation 
[224]. Importantly, BIM-23A760, a chimeric compound that 
activates SSTR2 and D2R, acutely decreased growth hor-
mone and prolactin secretion in pituitary tumors, but long-
term effects disappeared due to a dopaminergic metabolite 
that may interfere with the activity of the parent molecule 
[221]. An open-label, multicenter clinical trial in patients 
with carcinoid syndrome was started for evaluating the effi-
cacy of BIM-23A760. Unfortunately, this study was prema-
turely terminated and primary/secondary outcomes were not 
analyzed (NCT01018953). Currently research is focused on 
the improvement of chimeric molecules that could keep a 
long-term effect.
5  Conclusions
The number of systemic treatment options for NETs aiming 
to control either hormone production and/or tumor growth 
has significantly increased and improved in the last years. 
A higher number of clinical trials and approved therapeu-
tic agents have further facilitated the management of NET 
patients. SSAs were found to have antiproliferative effects, 
next to their inhibitory action on hormone secretion, and can 
induce sustained stabilization in grade 1–2 NETs. If pro-
gression occurs under SSAs therapy, PRRT seems to be the 
most rational second-line treatment, considering its efficacy 
and side effects, with everolimus and sunitinib (for PNET) 
as the next options. To further improve PFS and hopefully 
OS, further randomized studies are needed to establish the 
optimal role, sequence, and/or combination(s) of the cur-
rently available and emerging treatment options. In addi-
tion, future studies should further characterize (epi)genetic 
aspects and regulatory pathways of NETs to identify new 
targets for medical therapy.
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